Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206556 · ClinicalTrials.gov registry record
IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody
A clinical trial, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Completed
- Registry status
- 97
- Enrollment target
NCT01206556: Completed study, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
NCT01206556 is a clinical trial that has completed, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 97 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01206556 has completed, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
Study Summary
This study is being done to evaluate how long the immune response from the Human Papilloma Virus (HPV) vaccine you / your child received persists. The immune response occurred after immunization and is what protects you/your child from HPV disease. You / your child received this vaccine as part of an earlier study (P1047). The vaccine is called Human Papillomavirus Vaccine (QHPV Vaccine, also known as GARDASIL®). The study will check to see if the protective effects (called "antibodies") produced by the vaccine have lasted, and for how long these effects will continue to last. You will not be given any medications or vaccines as part of this follow-up study.
Primary Outcome
To determine the HPV-type specific antibody levels at 2, 3.5, and 5 years after completion of the QHPV vaccine schedule for each of the arms in P1047 and compare them to published levels of QHPV-induced antibody levels present in age-similar children IMPAACT P1085 without HIV infection at these time intervals after QHPV vaccination.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-08 |
What the finished NCT01206556 record still lists
NCT01206556 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 97 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01206556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01206556 about?
NCT01206556 is a clinical study titled "IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody". This study is being done to evaluate how long the immune response from the Human Papilloma Virus (HPV) vaccine you / your child received persists. The immune response occurred after immunization and is what protects you/your child from HPV disease. You / your child received this vaccine as part of a...
What is the current status of trial NCT01206556?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2010-05. Estimated completion is 2013-08.
Who is sponsoring clinical trial NCT01206556?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia